Search the Newsreel

Rhythm Pharmaceuticals in spotlight: earnings test for HO launch By Investing.com

Rhythm Pharmaceuticals (RYTM) is under investor scrutiny as it prepares to release its Q2 earnings, which will provide the first detailed look at revenue from its newly approved treatment for acquired hypothalamic obesity (HO). Analysts are bullish, expecting an 81-cent loss per share on …

Rhythm Pharmaceuticals (RYTM) Stock Looks Above Fair Value But Sales Stay Strong

Rhythm Pharmaceuticals (RYTM) has seen substantial stock growth over the past five years, but its current valuation suggests it is now overvalued, trading at a P/S ratio of 31.3x compared to an industry average of 10.5x and a fair P/S of 19.8x. While strong …

(RYTM) Volatility Zones as Tactical Triggers

Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) is showing divergent sentiment across horizons, indicating choppy conditions. AI models have generated three distinct trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, each with specific entry, target, and stop loss levels. …

Rhythm Pharmaceuticals, Inc. $RYTM Shares Sold by Janus Henderson Group PLC

Rhythm Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:RYTM

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) generated a total revenue of $194.77 million USD last year. The majority of this revenue, $189.76 million USD, came from its Therapeutics segment. The United States was the largest geographical contributor, accounting for $133.55 million USD of the revenue.

Rhythm Pharmaceuticals Inc (RYTM) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Rhythm Pharmaceuticals Inc (RYTM), detailing its current price momentum, support and resistance levels, and various technical indicator readings. It shows that RYTM's stock price is currently trading between resistance at $114.09 and support at $99.21, suggesting suitability …

RYTM|Rhythm Pharmaceuticals Inc|Price:105.800|Chg%:-0.730

Rhythm Pharmaceuticals Inc (RYTM) has strong fundamentals, high growth potential, and is considered fairly valued within the pharmaceuticals industry. Institutional ownership is high, and analysts largely rate it as a "Buy" with an expected upward trend in the medium term. The company specializes in …

Could Anticipated Q2 Earnings Beat Amid Weaker Profitability Reframe Rhythm Pharmaceuticals’ Growth Story (RYTM)?

In early August 2026, Rhythm Pharmaceuticals is scheduled to report quarterly results that analysts expect will show higher revenue but a year-over-year earnings decline, with many anticipating a potential earnings beat versus consensus estimates. This combination of rising sales and the prospect of outperforming …

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Rhythm Pharmaceuticals, Inc. (RYTM) is predicted to surpass Q2 earnings estimates, despite an expected year-over-year decline in earnings but higher revenues. The company's Zacks Earnings ESP of +1.46% combined with a Zacks Rank #3 suggests a strong probability of an earnings beat. Investors will …

Rhythm Pharmaceuticals (RYTM) Projected to Announce Earnings on Tuesday

Rhythm Pharmaceuticals Inc (RYTM) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Rhythm Pharmaceuticals Inc (RYTM), highlighting its current valuation score of 9.55, which ranks 16th in the Pharmaceuticals industry. The P/E ratio is noted as -33.84, with other key metrics like P/B, P/S, and P/CF not yet disclosed …

Rhythm Pharmaceuticals Inc (RYTM) Cash Flow

This article provides a detailed historical cash flow statement for Rhythm Pharmaceuticals Inc (RYTM), displaying data quarterly and annually across several fiscal years. It includes operational, investing, and financing cash flow metrics, along with explanations of these financial terms and their significance. The data …

JPMorgan initiates Rhythm Pharmaceuticals stock at Overweight

JPMorgan initiated coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with an Overweight rating and a $145.00 price target, citing the company's potential to expand its Imcivree drug franchise. The firm believes Imcivree's recent expansion into acquired hypothalamic obesity and future indications like congenital hypothalamic obesity and …

Rhythm Pharmaceuticals Inc (RYTM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution — TradingKey

This article provides a brief overview of Rhythm Pharmaceuticals Inc (RYTM), highlighting its current stock price, market capitalization, and regional revenue breakdown. The company's revenue distribution shows significant contributions from both the United States and International markets. Financial data for specific business segments and …

Rhythm Pharmaceuticals (RYTM) Faces A Big Undervaluation Call, Is The Upside Already Priced In?

Rhythm Pharmaceuticals (RYTM) has captured investor interest due to a narrative suggesting it is 26.8% undervalued, with a fair value of $139.47 per share, significantly higher than its current $102.10. This valuation is heavily based on anticipated revenue growth from its drug setmelanotide and …

Rhythm Pharmaceuticals, Inc. $RYTM Shares Acquired by Orbimed Advisors LLC

Rhythm Pharmaceuticals, Inc. $RYTM Shares Bought by SummitTX Capital L.P.

Rhythm Pharmaceuticals (RYTM) Q1 2023 Earnings Report - Results, Call & Slides

Rhythm Pharmaceuticals (RYTM) released its Q1 2023 earnings report, missing both EPS and revenue expectations. The company reported an actual EPS of -$16.11 against a consensus of -$12.57, and actual revenue of $200.81M compared to an expected $212.19M, although showing significant year-over-year revenue growth …

Rhythm Pharmaceuticals, Inc. Revenue Breakdown – FWB:1RV

Rhythm Pharmaceuticals, Inc. (FWB:1RV) generated €165.83 million in revenue last year, with its Therapeutics segment being the top performer, contributing €161.56 million. The United States was the largest geographical contributor, accounting for €113.71 million of the revenue. This data highlights the company's key revenue …

Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm

Kuehn Law, a shareholder litigation law firm, is investigating potential breaches of fiduciary duties by officers and directors of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) due to alleged self-dealing. The firm is encouraging long-term RYTM stockholders to contact them for a free consultation regarding potential …

RYTM stock trades around recent range as Rhythm Pharmaceuticals highlights setmelanotide growth

Rhythm Pharmaceuticals (RYTM) stock is trading within its recent range as the company reports double-digit revenue growth for its rare obesity therapy, setmelanotide. Q1 2026 revenue reached $29 million, up 38% year-over-year, driven by increased patient uptake. While the company remains loss-making, its operating …

Rhythm Pharmaceuticals schedules live Q2 results webcast Aug. 4

Rhythm Pharmaceuticals (Nasdaq: RYTM) will report its second-quarter 2026 financial results and provide a corporate update during a live conference call and webcast on Tuesday, August 4, 2026, at 8:00 a.m. ET. The company, a commercial-stage biopharmaceutical firm, focuses on rare neuroendocrine diseases, with …

Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

Rhythm Pharmaceuticals, Inc. announced it will host a conference call and webcast on Tuesday, August 4, 2026, at 8:00 a.m. ET to discuss its second quarter 2026 financial results and provide a corporate update. The company is a commercial-stage biopharmaceutical firm focused on rare …

Rhythm Pharmaceuticals, Inc. (RYTM) Investor Outlook: Strong Buy Ratings Signal Potential 31% Upside

Rhythm Pharmaceuticals, Inc. (RYTM) is a biopharmaceutical company focusing on treatments for rare neuroendocrine diseases, driving investor interest with strong analyst ratings and growth potential. Despite current negative EPS and high R&D costs, its 83.8% revenue growth and flagship product IMCIVREE in Phase 3 …

Law firm probes Rhythm Pharmaceuticals officers for possible self-dealing harming shareholders

Kuehn Law, PLLC is investigating officers and directors of Rhythm Pharmaceuticals, Inc. for alleged breaches of fiduciary duties through potential self-dealing. This investigation could result in damages for shareholders and corporate governance reforms. Long-term shareholders are advised to contact the law firm for a …

Is Rhythm Pharmaceuticals Poised for a Breakthrough in Hypothalamic Obesity

Rhythm Pharmaceuticals' drug, setmelanotide, shows promising Phase 3 results for acquired hypothalamic obesity (HO), targeting a potential FDA approval by March 20, 2026. This condition represents a significant unmet medical need with a substantial global patient population. Analysts project significant revenue growth for Rhythm …

Wells Fargo Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $155

Wells Fargo has reiterated its Buy rating for Rhythm Pharmaceuticals (RYTM.US) and maintained its price target at $155. This continued positive outlook suggests the firm sees sustained value and growth potential for the pharmaceutical company.

Rhythm Pharmaceuticals Stock On Fire: Up 28% With 12-Day Winning Streak

RYTM Forecast — Price Target — Prediction for 2027

8-Day Rally Sends Rhythm Pharmaceuticals Stock Up 24%

Rhythm Pharmaceuticals: The Rare Obesity Platform Is Becoming A Commercial Engine

Rhythm (RYTM) Q1 2026 Earnings Call Transcript

Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday

Rhythm Pharmaceuticals Q1 Earnings Call Highlights

Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue Estimates